Search

Your search keyword '"Alexandra Zduniak"' showing total 6 results
Start Over Author "Alexandra Zduniak"
6 results on '"Alexandra Zduniak"'

1. Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell lymphoma: A case report

Author

Vincent Camus, Pascaline Etancelin, Fanny Drieux, Elena‐Liana Veresezan, Jean‐Michel Picquenot, Dominique Penther, Mathieu Viennot, Philippe Ruminy, Nathalie Contentin, Emilie Lemasle, Stéphane Leprêtre, Sydney Dubois, Juliette Penichoux, Aspasia Stamatoullas, Alexandra Zduniak, Hélène Lanic, and Fabrice Jardin

Subjects
allogenic stem cell transplantation, belinostat, complete response, HDAC inhibitor, nTFHL‐AI, PTCL, Medicine, Medicine (General), R5-920
Abstract

Key Clinical Message This case report highlights the potential of belinostat for the treatment of relapsed/refractory peripheral T‐cell lymphomas, for which effective therapies are still scarce. Abstract Peripheral T‐cell lymphomas have an aggressive disease course associated with poor outcomes. We report a young patient with highly pretreated relapsed/refractory nodal follicular helper T‐cell lymphoma (angioimmunoblastic‐type [nTFHL‐AI]), who successfully received an allogeneic stem cell transplantation following belinostat therapy. The complete hematologic response achieved has lasted more than 2 years.

Published
2023
Full Text
View/download PDF

2. Successful treatment of T/myeloid mixed‐phenotype acute leukemia with the translocation (10;11)(p13;q14) PICALM/AF10 with 3 + 7 myeloid standard treatment: A case report

Author

Daphné Krzisch, Alexandra Zduniak, Elena‐Liana Veresezan, Sylvie Daliphard, Nathalie Contentin, Dominique Penther, Pascaline Etancelin, Fabrice Jardin, and Vincent Camus

Subjects
mixed‐phenotype acute leukemia, PICALM‐AF10, translocation (1011)(p13q14), Medicine, Medicine (General), R5-920
Abstract

Abstract The translocation PICALM/AF10 is described in multilineage diseases. We report a patient with PICALM/AF10 T/myeloid mixed‐phenotype acute leukemia who achieved durable complete remission after AML‐like treatment suggesting a myeloid origin.

Published
2021
Full Text
View/download PDF

3. Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy

Author

Alexandra, Zduniak, Emilie, Lévêque, Anne, Perdrix, Pascaline, Etancelin, Anne-Lise, Ménard, Pascal, Lenain, Nathalie, Contentin, Louis-Ferdinand, Pépin, Stéphane, Leprêtre, Emilie, Lemasle, Hélène, Lanic, Aspasia, Stamatoullas-Bastard, Leila, Kammoun-Quique, Hervé, Tilly, Fabrice, Bauer, Fabrice, Jardin, and Vincent, Camus

Subjects
Cancer Research, Oncology, Hematology
Abstract

We conducted a single-center retrospective study to assess cardiovascular (CV) toxicity and treatment discontinuation for CV toxicity in diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) patients treated with immunochemotherapy (R-CHOP-like). Between 2006 and 2017, 433 patients were included (DLBCL

Published
2022
Full Text
View/download PDF

4. Successful treatment of T/myeloid mixed‐phenotype acute leukemia with the translocation (10;11)(p13;q14) PICALM/AF10 with 3 + 7 myeloid standard treatment: A case report

Author

Sylvie Daliphard, Vincent Camus, Pascaline Etancelin, Elena-Liana Veresezan, Fabrice Jardin, Dominique Penther, Nathalie Contentin, Alexandra Zduniak, and Daphné Krzisch

Subjects
Myeloid, lcsh:Medicine, Chromosomal translocation, Case Report, Case Reports, 030204 cardiovascular system & hematology, PICALM, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, translocation (1011)(p13q14), medicine, mixed‐phenotype acute leukemia, Acute leukemia, lcsh:R5-920, Mixed phenotype acute leukemia, business.industry, Standard treatment, lcsh:R, Complete remission, General Medicine, PICALM‐AF10, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Cancer research, business, lcsh:Medicine (General)
Abstract

The translocation PICALM/AF10 is described in multilineage diseases. We report a patient with PICALM/AF10 T/myeloid mixed‐phenotype acute leukemia who achieved durable complete remission after AML‐like treatment suggesting a myeloid origin.

Published
2021

5. High Prevalence of Pre-Existing Sarcopenia in Critically Ill Patients with Hematologic Malignancies Admitted to the Intensive Care Unit for Sepsis or Septic Shock

Author

Antoine Herault, Emilie Lévêque, Simon Draye-Carbonnier, Pierre Decazes, Alexandra Zduniak, Romain Modzelewski, Julie Libraire, Najate Achamrah, Anne-Lise Ménard, Pascal Lenain, Nathalie Contentin, Maximilien Grall, Stéphane Leprêtre, Emilie Lemasle, Hélène Lanic, Mustafa Alani, Aspasia Stamatoullas-Bastard, Hervé Tilly, Fabrice Jardin, Fabienne Tamion, and Vincent Camus

Subjects
History, Nutrition and Dietetics, Polymers and Plastics, Endocrinology, Diabetes and Metabolism, Business and International Management, Industrial and Manufacturing Engineering
Published
2022
Full Text
View/download PDF

6. Outcomes after intensive care unit admission in newly diagnosed diffuse large B-cell lymphoma patients: A real-life study

Author

J. Lequesne, Aspasia Stamatoullas-Bastard, Louis-Ferdinand Pepin, Anne-Lise Menard, Vincent Camus, Emilie Lemasle, Alexandra Zduniak, Hervé Tilly, Fabienne Tamion, Fabrice Jardin, Nathalie Contentin, Sorina-Dana Mihailescu, Pascal Lenain, Hélène Lanic, and Stéphane Leprêtre

Subjects
Male, medicine.medical_specialty, health care facilities, manpower, and services, Disease-Free Survival, law.invention, Sepsis, 03 medical and health sciences, 0302 clinical medicine, Patient Admission, law, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Hospital Mortality, Cyclophosphamide, Aged, Retrospective Studies, Septic shock, business.industry, Retrospective cohort study, Hematology, General Medicine, Middle Aged, medicine.disease, Intensive care unit, Survival Rate, Regimen, Intensive Care Units, Respiratory failure, Doxorubicin, Vincristine, 030220 oncology & carcinogenesis, Cohort, Prednisone, Female, Lymphoma, Large B-Cell, Diffuse, business, Rituximab, Diffuse large B-cell lymphoma, 030215 immunology
Abstract

We conducted a retrospective study to analyze the prognostic factors impacting the overall survival (OS) and progression-free survival (PFS) of diffuse large B-cell lymphoma (DLBCL) patients undergoing first-line therapy and admitted to intensive care unit (ICU) compared to a control cohort who did not required ICU admission. Between January 1, 2008, and December 31, 2018, 828 patients were diagnosed with DLBCL at our institution, including 72 patients who were required ICU admission during disease course. Among them, forty-five patients undergoing homogeneous first-line therapy with /R-CHOP-like regimen and ICU-admitted were selected for the present analysis. Control "non-ICU" DLBCL patients were matched by age, IPI score and treatment received. The median age at ICU admission was 65 years, 97.8% of patients displayed advanced-stage disease (III/IV), and 84.4% had a high IPI score (3-5). The main reasons for ICU admission were acute respiratory failure (40.0%) and septic shock (33.3%). The ICU mortality rate was 33.3%. The 2-year PFS was lower in ICU survivors patients than in non-ICU patients: 31.7% (95% CI 18.5-54.1) vs 60.8% (95% CI 51.2-72.1, P = .00049). Admission to the ICU is an event that clearly impacts the outcomes of patients with DLBCL, until 2 years after the event. ICU prognosis seems mainly related to critical patient severity at admission rather than lymphoma-related prognostic factors (IPIs), suggesting that ICU admission criteria should not be based only on the lymphoma prognosis.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results